OCULAR THERAPEUTIX IN

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

01 3月 2024 11:02:47 条件 NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

26 2月 2024 08:47:12 条件 NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

23 2月 2024 09:33:55 条件 NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

22 2月 2024 08:45:24 条件 NetDania Notify

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22 2月 2024 06:32:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22 2月 2024 06:31:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22 2月 2024 06:30:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

15 2月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

13 2月 2024 06:38:24 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

25 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

18 12月 2023 15:01:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

13 12月 2023 21:09:58 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

13 12月 2023 15:01:11 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

08 11月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

07 11月 2023 15:01:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

01 11月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

24 10月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

03 10月 2023 15:01:00 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

06 9月 2023 07:01:11 条件 Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

09 8月 2023 07:00:00 条件 Nasdaq GlobeNewswire